Fish Oil side effects: what 89,854 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Omegaven
Who reports
89,854 reports · 49% serious · 4,529 with death outcome · 62% female
Used for
Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). Limitations of Use: • Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients .
What it is
Omegaven (fish oil triglycerides) is a sterile, nonpyrogenic, white, homogenous emulsion for intravenous infusion as a supply of calories in patients with PNAC.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,138 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Subcutaneous drug absorption impaired | 138 | 79.1 65.2–95.9ROR 79.2 · calibrated p 8e-7 ✓ | 58.6 EB05 50.8 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=138 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Hypocholesterolaemia | 77 | 77.7 60.0–100.7ROR 77.8 · calibrated p 1e-6 ✓ | 57.5 EB05 47.5 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=76 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| C-reactive protein | 225 | 76.8 66.1–89.4ROR 77.0 · calibrated p 9e-7 ✓ | 57.5 EB05 51.5 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=225 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Deep vein thrombosis postoperative | 469 | 73.3 66.0–81.3ROR 73.6 · calibrated p 1e-6 ✓ | 55.6 EB05 51.5 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=469 · ♀ 100% (drug 62%) | not reported in cached trials |
| Lupus vulgaris | 197 | 46.2 39.6–53.8ROR 46.3 · calibrated p 2e-5 ✓ | 38.5 EB05 34.2 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=197 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 108 | 44.9 36.6–55.2ROR 45.0 · calibrated p 3e-5 ✓ | 37.5 EB05 31.9 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=108 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 471 | 41.4 37.5–45.6ROR 41.6 · calibrated p 4e-5 ✓ | 35.2 EB05 32.6 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=471 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Facet joint syndrome | 475 | 41.3 37.4–45.5ROR 41.5 · calibrated p 4e-5 ✓ | 35.1 EB05 32.5 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=475 · ♀ 100% (drug 62%) · 93% clinician | not reported in cached trials |
| X-ray abnormal | 255 | 38.8 34.0–44.3ROR 38.9 · calibrated p 7e-5 ✓ | 33.2 EB05 30.0 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=255 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Peripheral venous disease | 527 | 35.4 32.3–38.8ROR 35.6 · calibrated p 1e-4 ✓ | 30.7 EB05 28.6 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=522 · ♀ 100% (drug 62%) · 93% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 264 | 35.1 30.8–39.9ROR 35.2 · calibrated p 1e-4 ✓ | 30.5 EB05 27.5 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=259 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Dislocation of vertebra | 283 | 33.9 29.9–38.4ROR 34.0 · calibrated p 1e-4 ✓ | 29.6 EB05 26.8 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=283 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Rheumatic fever | 532 | 32.3 29.5–35.3ROR 32.4 · calibrated p 2e-4 ✓ | 28.4 EB05 26.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=532 · ♀ 100% (drug 62%) · 95% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 817 | 30.2 28.1–32.5ROR 30.5 · calibrated p 2e-4 ✓ | 26.8 EB05 25.3 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious PRR 31.8 · ♀ 100% (drug 62%) · 96% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 841 | 30.1 28.0–32.3ROR 30.4 · calibrated p 2e-4 ✓ | 26.7 EB05 25.2 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious PRR 31.5 · ♀ 100% (drug 62%) · 93% clinician | not reported in cached trials |
| Rheumatoid factor positive | 639 | 29.0 26.7–31.4ROR 29.2 · calibrated p 3e-4 ✓ | 25.8 EB05 24.2 · IC025 +4.5 3/3 methods agree | Lab value / disease marker | serious n=639 · ♀ 100% (drug 62%) · 95% clinician | not reported in cached trials |
| Muscle injury | 894 | 28.4 26.5–30.5ROR 28.7 · calibrated p 3e-4 ✓ | 25.4 EB05 24.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious PRR 32.2 · ♀ 97% (drug 62%) · 92% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, insomnia type | 590 | 23.5 21.6–25.5ROR 23.6 · calibrated p 9e-4 ✓ | 21.4 EB05 19.9 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=579 · ♀ 100% (drug 62%) · 91% clinician | not reported in cached trials |
| Folliculitis | 882 | 21.7 20.3–23.2ROR 21.9 · calibrated p 0.001 ✓ | 19.9 EB05 18.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious PRR 27.4 · ♀ 100% (drug 62%) · 92% clinician | not reported in cached trials |
| Helicobacter infection | 834 | 20.7 19.3–22.2ROR 20.9 · calibrated p 0.002 ✓ | 19.1 EB05 18.0 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious PRR 23.7 · ♀ 100% (drug 62%) · 92% clinician | not reported in cached trials |
| C-reactive protein abnormal | 502 | 19.8 18.0–21.6ROR 19.9 · calibrated p 0.002 ✓ | 18.3 EB05 17.0 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=500 · ♀ 100% (drug 62%) · 94% clinician | not reported in cached trials |
| Pemphigus | 921 | 18.6 17.4–19.9ROR 18.8 · calibrated p 0.003 ✓ | 17.3 EB05 16.4 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious PRR 20.5 · ♀ 100% (drug 62%) · 94% clinician | not reported in cached trials |
| Lip dry | 616 | 17.2 15.8–18.6ROR 17.3 · calibrated p 0.004 ✓ | 16.0 EB05 15.0 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=583 · ♀ 100% (drug 62%) | not reported in cached trials |
| Porphyria acute | 92 | 16.6 13.4–20.5ROR 16.6 · calibrated p 0.005 ✓ | 15.5 EB05 13.0 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=92 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Hand deformity | 822 | 15.6 14.5–16.7ROR 15.7 · calibrated p 0.006 ✓ | 14.6 EB05 13.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 18.7 · ♀ 100% (drug 62%) · 92% clinician | not reported in cached trials |
| Retinitis | 100 | 14.8 12.1–18.1ROR 14.8 · calibrated p 0.008 ✓ | 13.9 EB05 11.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=100 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Pericarditis | 974 | 14.4 13.5–15.4ROR 14.6 · calibrated p 0.008 ✓ | 13.6 EB05 12.9 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 16.2 · ♀ 100% (drug 62%) · 93% clinician | not reported in cached trials |
| Joint range of motion decreased | 778 | 14.4 13.4–15.4ROR 14.5 · calibrated p 0.008 ✓ | 13.6 EB05 12.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious PRR 19.7 · ♀ 95% (drug 62%) | not reported in cached trials |
| Bursitis | 651 | 13.3 12.2–14.3ROR 13.3 · calibrated p 0.011 ✓ | 12.6 EB05 11.8 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 16.7 · ♀ 96% (drug 62%) | not reported in cached trials |
| Breast cancer stage iii | 340 | 13.0 11.6–14.5ROR 13.0 · calibrated p 0.013 ✓ | 12.3 EB05 11.2 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=340 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Autoimmune disorder | 497 | 12.7 11.6–13.9ROR 12.8 · calibrated p 0.013 ✓ | 12.1 EB05 11.2 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 15.0 · ♀ 100% (drug 62%) | not reported in cached trials |
| Synovitis | 911 | 12.4 11.6–13.2ROR 12.5 · calibrated p 0.015 ✓ | 11.8 EB05 11.1 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 14.5 · ♀ 100% (drug 62%) · 94% clinician | not reported in cached trials |
| Irritable bowel syndrome | 1,058 | 12.1 11.4–12.9ROR 12.2 · calibrated p 0.016 ✓ | 11.5 EB05 11.0 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious PRR 16.5 · ♀ 97% (drug 62%) | not reported in cached trials |
| Glossodynia (burning tongue/mouth pain) | 1,008 | 11.0 10.3–11.7ROR 11.1 · calibrated p 0.023 ✓ | 10.5 EB05 10.0 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 16.2 · ♀ 93% (drug 62%) | not reported in cached trials |
| Wound infection | 474 | 10.6 9.7–11.6ROR 10.6 · calibrated p 0.026 ✓ | 10.1 EB05 9.4 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 12.6 · ♀ 100% (drug 62%) | not reported in cached trials |
| Pustular psoriasis | 148 | 10.4 8.8–12.3ROR 10.4 · calibrated p 0.029 ✓ | 9.9 EB05 8.6 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=142 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Blepharospasm | 263 | 10.3 9.1–11.6ROR 10.3 · calibrated p 0.030 ✓ | 9.8 EB05 8.8 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=242 · ♀ 100% (drug 62%) | not reported in cached trials |
| Eyelid pain | 76 | 9.5 7.5–11.9ROR 9.5 · calibrated p 0.041 ✓ | 8.9 EB05 7.3 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Drug tolerance decreased | 108 | 9.3 7.7–11.3ROR 9.3 · calibrated p 0.043 ✓ | 8.8 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=101 · ♀ 100% (drug 62%) · 100% clinician | not reported in cached trials |
| Fibromyalgia | 929 | 9.2 8.7–9.9ROR 9.3 · calibrated p 0.041 ✓ | 8.9 EB05 8.4 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious PRR 12.9 · ♀ 98% (drug 62%) | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Tendon disorder | 479 | 3.02.7–3.2 | signal |
| Depression | 2,660 | 2.22.1–2.3 | signal |
| Fall / fracture | 3,158 | 1.91.9–2.0 | raised |
| Hyperglycaemia / diabetes | 2,794 | 1.91.8–2.0 | raised |
| Serious infection | 5,553 | 1.71.6–1.7 | raised |
| Gi bleeding | 1,292 | 1.71.6–1.7 | raised |
| Liver injury | 2,087 | 1.61.6–1.7 | raised |
| Interstitial lung disease | 613 | 1.51.4–1.6 | raised |
| Opportunistic infection | 826 | 1.41.3–1.5 | raised |
| Arrhythmia / qt | 1,173 | 1.41.3–1.5 | raised |
| Anaemia | 1,809 | 1.41.3–1.5 | raised |
| Venous thromboembolism | 1,276 | 1.41.3–1.5 | raised |
| Pancreatitis | 472 | 1.41.2–1.5 | raised |
| Kidney injury | 2,270 | 1.21.1–1.2 | raised |
| Hyponatraemia | 387 | 1.11.0–1.2 | raised |
| Thrombocytopenia | 991 | 1.11.0–1.1 | no difference |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Fish Oil as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT01351805 — Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain (N=25871, NA; 24 AE terms posted; arms: Active Vitamin D/ Active Omega-3 Fatty A; Active Vitamin D/ Active Omega-3 Placebo; Active Omega-3 Fatty Acids, Placebo Vita; Omega-3 Fatty Acids Placebo/ Placebo Vit)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 8,358 | 2.5 2.5–2.6ROR 2.7 · calibrated p 0.739 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.3 · serious PRR 3.1 | not reported in cached trials |
| Drug ineffective (drug did not work) | 6,212 | 1.1 1.1–1.1ROR 1.1 · calibrated p 0.378 | 1.1 EB05 1.1 · IC025 +0.1 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.6 | not reported in cached trials |
| Diarrhoea (diarrhea) | 6,095 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.898 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.0 · serious PRR 2.6 | NCT01351805: 2781/6,463 (43.0%) on Fish Oil; 2730/6,464 (42.2%) control |
| Nausea | 6,077 | 1.8 1.8–1.8ROR 1.9 · calibrated p 0.866 | 1.8 EB05 1.8 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 2.3 | NCT01351805: 1748/6,463 (27.0%) on Fish Oil; 1771/6,464 (27.4%) control |
| Headache | 5,792 | 2.2 2.1–2.2ROR 2.2 · calibrated p 0.927 | 2.2 EB05 2.1 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.8 | not reported in cached trials |
| Pain | 5,439 | 2.1 2.0–2.1ROR 2.1 · calibrated p 0.982 | 2.1 EB05 2.0 · IC025 +1.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.4 · serious PRR 2.5 | NCT01351805: 2439/6,463 (37.7%) on Fish Oil; 2421/6,464 (37.5%) control |
| Dizziness | 4,814 | 2.3 2.2–2.3ROR 2.3 · calibrated p 0.884 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.7 | not reported in cached trials |
| Arthralgia (joint pain) | 4,656 | 2.6 2.6–2.7ROR 2.7 · calibrated p 0.721 | 2.6 EB05 2.6 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.6 · serious PRR 3.6 | not reported in cached trials |
| Pruritus (itching) | 4,383 | 2.7 2.6–2.8ROR 2.8 · calibrated p 0.690 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.2 · serious PRR 3.3 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 4,382 | 1.8 1.8–1.9ROR 1.9 · calibrated p 0.862 | 1.8 EB05 1.8 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 1.6 · serious PRR 2.1 | not reported in cached trials |
| Asthenia (weakness) | 4,136 | 2.6 2.5–2.7ROR 2.7 · calibrated p 0.748 | 2.6 EB05 2.5 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.2 · serious PRR 3.1 | not reported in cached trials |
| Rash | 3,907 | 2.1 2.0–2.2ROR 2.2 · calibrated p 0.970 | 2.1 EB05 2.0 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 3.2 | NCT01351805: 1629/6,463 (25.2%) on Fish Oil; 1639/6,464 (25.4%) control |
| Off label use (used outside approved label) | 3,836 | 1.0 1.0–1.1ROR 1.0 · calibrated p 0.328 | 1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.1 · serious PRR 1.3 | not reported in cached trials |
| Pain in extremity | 3,360 | 2.7 2.6–2.8ROR 2.7 · calibrated p 0.717 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.5 · serious PRR 3.4 | not reported in cached trials |
| Vomiting | 3,354 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.769 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 2.2 | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Subcutaneous drug absorption impaired — n=138, PRR 79.1
- Hypocholesterolaemia — n=77, PRR 77.7
- Deep vein thrombosis postoperative — n=469, PRR 73.3
- Lupus vulgaris — n=197, PRR 46.2
- Facet joint syndrome — n=475, PRR 41.3
- Peripheral venous disease — n=527, PRR 35.4
- Adjustment disorder with depressed mood — n=264, PRR 35.1
- Dislocation of vertebra — n=283, PRR 33.9
- Rheumatic fever — n=532, PRR 32.3
- Duodenal ulcer perforation — n=841, PRR 30.1
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Fish Oil?
In FDA FAERS, the most frequently co-reported reaction terms for Fish Oil are fatigue, diarrhoea, nausea, headache, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Fish Oil have an FDA boxed warning?
No. The FDA label retrieved for Fish Oil has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Fish Oil causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 5d9d0b24-e139-48bf-ab2d-536fb59cf8e0, effective 20250905; matched on
openfda.generic_name.exact:"FISH OIL" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,178 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
FISH OIL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.